RBT has developed a proprietary method for skin whitening through the use of an enzyme derived from a harmless fungus. The RBT product can also be used to treat pigmented lesions. Syneron’s investment will enable RBT to further the development of its innovative product, as well as to pursue other applications for the enzyme to treat other pigmentation disorders. As part of the investment agreement, Syneron will have exclusive, worldwide distribution rights.
Doron Gerstel, CEO of Syneron, said: “Our investment in RBT, like our other investments in complementary technologies, will serve to further diversify both our portfolio of product offerings in the aesthetic sector and our business model.”